Corbus Adds AstraZeneca Dealmaker to Board Ahead of Key Clinical Readouts
Event summary
- Corbus Pharmaceuticals appointed Brent Pfeiffenberger, former Neogene Therapeutics COO (acquired by AstraZeneca in 2023), to its board of directors on May 14, 2026.
- Pfeiffenberger currently serves as CEO of Century Therapeutics and brings 20 years of oncology commercialization experience from Bristol Myers Squibb.
- Corbus expects to present updated Phase 1/2 data for CRB-701 at the 2026 ASCO Annual Meeting (May 29 – June 2) and initiate a registrational study for CRB-701 in second-line HNSCC this summer.
- The CANYON-1 Phase 1b trial for CRB-913 (obesity treatment) is on track to complete in summer 2026.
The big picture
Corbus's appointment of Pfeiffenberger signals a strategic pivot toward leveraging deep commercialization expertise ahead of critical clinical milestones. The move comes as the company navigates the transition from clinical-stage to potential commercialization, with Pfeiffenberger's track record in oncology commercialization and corporate evolution positioning Corbus for key regulatory and market decisions. The addition underscores the growing trend of biopharma companies fortifying boards with M&A and commercialization specialists as they approach inflection points.
What we're watching
- Regulatory Alignment
- Whether Corbus can sustain its broad alignment with the FDA on the registration path for CRB-701 in HNSCC through the upcoming registrational study.
- Clinical Momentum
- The pace at which Corbus advances both CRB-701 and CRB-913 programs, particularly with key data readouts expected this summer.
- Board Influence
- How Pfeiffenberger's experience in steering Neogene's acquisition by AstraZeneca will shape Corbus's strategic direction and potential exit opportunities.
Related topics